Intravenous immunoglobulin treatment in a HIV-1 positive patient with Guillain-Barré syndrome

Int Immunopharmacol. 2015 Dec;29(2):964-965. doi: 10.1016/j.intimp.2015.09.023. Epub 2015 Oct 1.

Abstract

We report the case of an HIV-1 positive patient with primary demyelinating neuropathy (Guillain-Barré syndrome); after intravenous immunoglobulin treatment (IVIG), he presented with an increase in CD4 and CD8 cell counts and a decrease in plasma viral load. Currently, there is little reported research regarding IVIG treatment in adults with HIV-1. The present report brings further evidence regarding the possible benefit of IVIG in HIV-1 infected patients, providing a novel perspective on treatment.

Keywords: Guillain-Barré syndrome; HIV-1;; Intravenous immunoglobulin;.

Publication types

  • Case Reports

MeSH terms

  • CD4-Positive T-Lymphocytes / drug effects
  • CD8-Positive T-Lymphocytes / drug effects
  • Guillain-Barre Syndrome / complications*
  • HIV Seropositivity / complications*
  • HIV Seropositivity / drug therapy*
  • HIV Seropositivity / virology
  • HIV-1*
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Male
  • Treatment Outcome
  • Viral Load
  • Young Adult

Substances

  • Immunoglobulins, Intravenous